Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi-Aventis 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Sanofi-Aventis 4Q

Pharmaceutical sales were up 3% in the quarter and for the year to $9.1 billion and $35.1 billion, respectively. Lovenox sales were $1.1 billion in the quarter (+8%) and $3.9 billion for the year (+11%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi-Aventis

4Q Revenues: $10.1 billion (+3%)

4Q Earnings: $2.3 billion (+14%)

FY Revenues: $39.1 billion (-2%)

FY Earnings: $10.2 billion (+3%)

Comments: Pharmaceutical sales were up 3% in the quarter and for the year to $9.1 billion and $35.1 billion, respectively. Lovenox sales were $1.1 billion in the quarter (+8%) and $3.9 billion for the year (+11%). Plavix sales were $936.5 million in the quarter (+10%) and $3.7 billion for the year (+11%). Lantus sales were $1.0 billion in the quarter (+25%) and $3.5 billion for the year (+30%). Taxotere sales were $767.7 million in the quarter (+12%) and $2.9 billion for the year (+13%). Eloxatin sales were down 5% in the quarter to $503.7 million and down 6% for the year to $1.9 billion. R&D expenses were $1.9 billion in the quarter (+3%) and $6.5 billion for the year (+1%). Costs from the discontinuation of programs (primarily Acomplia) had a negative effect of approximately one percent.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters